AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39119627 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare professionals (HCPs)
Number of subjects: 8000
Study 39119698 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of trimethylamine
Number of subjects: 11768
Study 39119705 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening binge alcohol consumption
Number of subjects: 26
Study 39119705 — intervention group
Group type: COMPARATOR
Intervention: Fluid control
Number of subjects: 26
Study 39119911 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem-ER
Number of subjects: 103
Study 39119911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 39119917 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT (Roche Diagnostics)
Number of subjects: 754
Study 39119917 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI (Siemens Healthineers)
Number of subjects: 754
Study 39119964 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT plus DAPT
Number of subjects: 240
Study 39119964 — intervention group
Group type: COMPARATOR
Intervention: DAPT alone
Number of subjects: 240
Study 39119981 — intervention group
Group type: EXPERIMENTAL
Intervention: Study pacifier
Number of subjects: 451
Study 39119981 — intervention group
Group type: COMPARATOR
Intervention: Non-study pacifier
Number of subjects: 451
Study 39119981 — intervention group
Group type: EXPERIMENTAL
Intervention: Digit sucking for 12 months or more
Number of subjects: 451
Study 39120078 — intervention group
Group type: COMPARATOR
Intervention: Level 1 (health education+objective monitoring, n=26)
Number of subjects: 84
Study 39120078 — intervention group
Group type: COMPARATOR
Intervention: Level 2 (asynchronous contact, level 1+prerecorded exercise videos, n=30)
Number of subjects: 84
Study 39120078 — intervention group
Group type: COMPARATOR
Intervention: Level 3 (synchronous contact, level 1+videoconference group exercise, n=28)
Number of subjects: 84
Study 39120779 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Think (Cognitive Restructuring Digital Mental Health Intervention)
Number of subjects: 0
Study 39120779 — intervention group
Group type: COMPARATOR
Intervention: Project Share (Supportive Therapy)
Number of subjects: 0
Study 39120786 — intervention group
Group type: EXPERIMENTAL
Intervention: LEM 5 mg (Study 304)
Number of subjects: 1006
Study 39120786 — intervention group
Group type: EXPERIMENTAL
Intervention: LEM 10 mg (Study 304)
Number of subjects: 1006
Study 39120786 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem tartrate extended-release 6.25 mg (Study 304)
Number of subjects: 1006
Study 39120786 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Study 304)
Number of subjects: 1006
Study 39120786 — intervention group
Group type: EXPERIMENTAL
Intervention: LEM 5 mg (Study 106)
Number of subjects: 1006
Study 39120786 — intervention group
Group type: EXPERIMENTAL
Intervention: LEM 10 mg (Study 106)
Number of subjects: 1006
Study 39120786 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Study 106)
Number of subjects: 1006
Study 39120786 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (Study 108)
Number of subjects: 1006
Study 39120786 — intervention group
Group type: EXPERIMENTAL
Intervention: LEM 5 mg (Study 108)
Number of subjects: 1006
Study 39120786 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Study 108)
Number of subjects: 1006
Study 39120786 — intervention group
Group type: EXPERIMENTAL
Intervention: LEM (all doses)
Number of subjects: 1006
Study 39120847 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab-adbm
Number of subjects: 0
Study 39120847 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab reference product
Number of subjects: 0
Study 39120848 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg every 4 weeks (Q4W)
Number of subjects: 1435
Study 39120850 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab-adbm (Cyltezo)
Number of subjects: 0
Study 39120850 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab Reference Product
Number of subjects: 0
Study 39120849 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Number of subjects: 698
Study 39120849 — intervention group
Group type: COMPARATOR
Intervention: Risankizumab
Number of subjects: 698
Study 39120895 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate practice facilitation
Number of subjects: 11789
Study 39120895 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 11789
Study 39120895 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 11789
Study 39120901 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt-based nicotine e-liquids
Number of subjects: 72
Study 39120901 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% nicotine e-liquids
Number of subjects: 72
Study 39120901 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol-flavored e-liquids
Number of subjects: 72
Study 39120901 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% nicotine e-liquids
Number of subjects: 72
Study 39120902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for insomnia integrated in best-evidence pain management (CBTi-BEPM)
Number of subjects: 123
Study 39120902 — intervention group
Group type: COMPARATOR
Intervention: Best-evidence pain management only (BEPM)
Number of subjects: 123
Study 39121101 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobbstop app (adapted for pregnant women)
Number of subjects: 10
Study 39121101 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups and individual interviews
Number of subjects: 10
Study 39121163 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 11
Study 39121437 — intervention group
Group type: EXPERIMENTAL
Intervention: Revumenib
Number of subjects: 94
Study 39121442 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic subtype analysis in children with standard-risk ALL
Number of subjects: 1381
Study 39121442 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic subtype, patterns of aneuploidy, and secondary genomic alterations
Number of subjects: 1381
Study 39121442 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive genomic analysis
Number of subjects: 1381
Study 39121442 — intervention group
Group type: COMPARATOR
Intervention: Children with high-risk B-ALL with favorable cytogenetic features
Number of subjects: 1381
Study 39121478 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated SMS text message intervention, 2 daily messages for 4 weeks
Number of subjects: 30
Study 39121557 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperammonemic crises (HA)
Number of subjects: 85
Study 39121557 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG monitoring during HA events
Number of subjects: 85
Study 39121557 — intervention group
Group type: EXPERIMENTAL
Intervention: Ammonia levels
Number of subjects: 85
Study 39121557 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine levels
Number of subjects: 85
Study 39121698 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of Ad26.COV2·S
Number of subjects: 0
Study 39121698 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 1 nAb levels against the Wuhan reference strain
Number of subjects: 0
Study 39121849 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatlimab (anti-LAG-3) plus Nivolumab (anti-PD-1)
Number of subjects: 0
Study 39121849 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab (anti-PD-1)
Number of subjects: 0
Study 39121849 — intervention group
Group type: COMPARATOR
Intervention: Relatlimab (anti-LAG-3)
Number of subjects: 0
Study 39121881 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (cALND)
Number of subjects: 1705
Study 39121881 — intervention group
Group type: COMPARATOR
Intervention: Sentinel lymph node biopsy only
Number of subjects: 1705
Study 39121990 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS-IBD online intervention for ∼12 weeks (including 6 × 30-min therapist sessions)
Number of subjects: 5000
Study 39121990 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine mental health screening
Number of subjects: 5000
Study 39121990 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS-IBD sessions completed
Number of subjects: 5000
Study 39121990 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviews with patients and healthcare providers
Number of subjects: 5000
Study 39121990 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant questionnaires at pre-intervention, 12-weeks (post-intervention), and 6-month follow-up
Number of subjects: 5000
Study 39121992 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion microintervention
Number of subjects: 0
Study 39121992 — intervention group
Group type: COMPARATOR
Intervention: No training control
Number of subjects: 0
Study 39122384 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Number of subjects: 600
Study 39122384 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysozyme
Number of subjects: 600
Study 39122384 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lactoferrin and lysozyme
Number of subjects: 600
Study 39122384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 39122389 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-volume constraints derived from statistical model in PredicT A
Number of subjects: 150
Study 39122389 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-volume constraints tested in PredicT B
Number of subjects: 150
Study 39122392 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowered Relief (ER)
Number of subjects: 0
Study 39122392 — intervention group
Group type: COMPARATOR
Intervention: Living Better (control)
Number of subjects: 0
Study 39122402 — intervention group
Group type: EXPERIMENTAL
Intervention: Cy-Tb skin test
Number of subjects: 350
Study 39122402 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard F TB assay
Number of subjects: 350
Study 39122402 — intervention group
Group type: COMPARATOR
Intervention: QFT-Plus assay
Number of subjects: 350
Study 39122404 — intervention group
Group type: EXPERIMENTAL
Intervention: KECHI plus usual care
Number of subjects: 800
Study 39122404 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 800
Study 39122403 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus access to supplemental speech-language teletherapy
Number of subjects: 210
Study 39122403 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 210
Study 39122636 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (cordectomy)
Number of subjects: 41
Study 39122636 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 41
Study 39122650 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 0
Study 39122650 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 0
Study 39122717 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab after R-CHOP induction
Number of subjects: 39
Study 39122717 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 39
Study 39122717 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall strategy including R-CHOP and blinatumomab
Number of subjects: 39
Study 39122726 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine, oxaliplatin, trastuzumab, and bevacizumab
Number of subjects: 36
Study 39122788 — intervention group
Group type: EXPERIMENTAL
Intervention: m-DOT (mobile Directly Observed Therapy) with hydroxyurea (15 mg/kg daily for three months)
Number of subjects: 86
Study 39122788 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring with hydroxyurea (15 mg/kg daily for three months)
Number of subjects: 86
Study 39122804 — intervention group
Group type: EXPERIMENTAL
Intervention: Male partner-targeted breastfeeding education and support interventions
Number of subjects: 408
Study 39122804 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 408
Study 39123054 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab every 2 weeks (Q2W)
Number of subjects: 0
Study 39123054 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab every 4 weeks (Q4W)
Number of subjects: 0
Study 39123054 — intervention group
Group type: COMPARATOR
Intervention: Lebrikizumab withdrawal (placebo Q2W)
Number of subjects: 0
Study 39123126 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive biomarkers of airway disease, Barrett's Esophagus, and gastroesophageal reflux disease (GERD)
Number of subjects: 4192
Study 39123126 — intervention group
Group type: COMPARATOR
Intervention: Sub-cohort control group
Number of subjects: 4192
Study 39123146 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation program (4-6 weeks duration)
Number of subjects: 68
Study 39123146 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prehabilitation)
Number of subjects: 68
Study 39123200 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent Supported Housing (ISH)
Number of subjects: 83
Study 39123200 — intervention group
Group type: COMPARATOR
Intervention: Housing rehabilitation as usual (HAU)
Number of subjects: 83
Study 39123210 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiauranib combined with etoposide (CE group)
Number of subjects: 43
Study 39123210 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiauranib combined with weekly-paclitaxel (CP group)
Number of subjects: 43
Study 39123210 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiauranib monotherapy (phase Ib study)
Number of subjects: 43
Study 39123434 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy (docetaxel, cisplatin, and 5-fluorouracil)
Number of subjects: 224
Study 39124551 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39124613 — intervention group
Group type: EXPERIMENTAL
Intervention: Coregistration with iFR
Number of subjects: 0
Study 39124613 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 0
Study 39125394 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide (0.05 mg/kg/day)
Number of subjects: 1411
Study 39125394 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition and/or intravenous fluids (mean volume)
Number of subjects: 1411
Study 39125451 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycocalyx dietary supplement (GDS), n = 25
Number of subjects: 50
Study 39125451 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 25
Number of subjects: 50
Study 39126603 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) formulation of donepezil at doses of 70, 140, and 280 mg
Number of subjects: 92
Study 39126603 — intervention group
Group type: COMPARATOR
Intervention: Oral formulation of donepezil at 10 mg
Number of subjects: 92
Study 39126720 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan (15 mg/hour intravenous)
Number of subjects: 409
Study 39126720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study 39126937 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg daily
Number of subjects: 30
Study 39126937 — intervention group
Group type: COMPARATOR
Intervention: Melatonin 3 mg daily
Number of subjects: 30
Study 39127063 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib continuation
Number of subjects: 32
Study 39127063 — intervention group
Group type: COMPARATOR
Intervention: Imatinib interruption
Number of subjects: 32
Study 39127450 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-Denmark (n = 1999)
Number of subjects: 3988
Study 39127450 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo group, n = 1989)
Number of subjects: 3988
Study 39127622 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon-performed adductor canal block (ACBs)
Number of subjects: 240
Study 39127622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided adductor canal block (ACBa)
Number of subjects: 240
Study 39127622 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adductor block)
Number of subjects: 240
Study 39127709 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-based deep learning techniques using ResNet 18 for diagnosing CAN
Number of subjects: 229
Study 39127709 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-based deep learning techniques using ResNet 18 for distinguishing definite or severe stages of CAN (dsCAN)
Number of subjects: 229
Study 39127709 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-based deep learning techniques using ResWide 50 for diagnosing dsCAN
Number of subjects: 229
Study 39127745 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab in combination with chemotherapy with or without bevacizumab
Number of subjects: 0
Study 39127745 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic assessments
Number of subjects: 0
Study 39127745 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal ctDNA parameters
Number of subjects: 0
Study 39127813 — intervention group
Group type: EXPERIMENTAL
Intervention: HPG/HA lubricant eye drops
Number of subjects: 70
Study 39127813 — intervention group
Group type: COMPARATOR
Intervention: CMC/HA lubricant eye drops
Number of subjects: 70
Study 39127924 — intervention group
Group type: EXPERIMENTAL
Intervention: StemMACS (Miltenyi Biotec)
Number of subjects: 0
Study 39127924 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIME-XV (FUJIFILM Irvine Scientific)
Number of subjects: 0
Study 39127924 — intervention group
Group type: COMPARATOR
Intervention: FBS-containing culture conditions
Number of subjects: 0
Study 39127924 — intervention group
Group type: EXPERIMENTAL
Intervention: HALPCs cultured in SFM
Number of subjects: 0
Study 39127924 — intervention group
Group type: EXPERIMENTAL
Intervention: HALPCs
Number of subjects: 0
Study 39128143 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted multisensory intervention combining Snoezelen, aromatherapy, and personal items
Number of subjects: 31
Study 39128143 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 39128497 — intervention group
Group type: EXPERIMENTAL
Intervention: Avocado-supplemented group (AVO, usual diet with 1 avocado/d)
Number of subjects: 994
Study 39128497 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet group (HAB, usual diet with limited avocado intake)
Number of subjects: 994
Study 39128498 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine test intake (range: 0-40 mg⋅kg) during early gestation (11-20 weeks)
Number of subjects: 25
Study 39128498 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine test intake (range: 0-40 mg⋅kg) during late gestation (31-40 weeks)
Number of subjects: 25
Study 39128498 — intervention group
Group type: COMPARATOR
Intervention: Current DRI recommendations for TSAA during pregnancy
Number of subjects: 25
Study 39128547 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte VLCSFAs (C20:0, C22:0, C24:0)
Number of subjects: 2383
Study 39128547 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher total VLCSFA concentrations
Number of subjects: 2383
Study 39128590 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanadelumab 300 mg every 2 weeks
Number of subjects: 21
Study 39128904 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoantigen DNA vaccine
Number of subjects: 9
Study 39128918 — intervention group
Group type: EXPERIMENTAL
Intervention: AKL-T01 digital therapeutic
Number of subjects: 221
Study 39129005 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Myofunctional Therapy (OMT)
Number of subjects: 39
Study 39129005 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 39
Study 39129005 — intervention group
Group type: COMPARATOR
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 39
Study 39129005 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CPAP and MAD)
Number of subjects: 39
Study 39129017 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-dentistry detection methods (intraoral camera)
Number of subjects: 0
Study 39129017 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-dentistry detection methods (smartphone camera)
Number of subjects: 0
Study 39129017 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral pathways (user fee removal)
Number of subjects: 0
Study 39129017 — intervention group
Group type: COMPARATOR
Intervention: Referral pathways (conventional care)
Number of subjects: 0
Study 39129017 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-dentistry detection methods (intraoral camera) and referral pathways (user fee removal)
Number of subjects: 0
Study 39129017 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-dentistry detection methods (smartphone camera) and referral pathways (user fee removal)
Number of subjects: 0
Study 39129149 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAP participation
Number of subjects: 287
Study 39129266 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 0
Study 39129266 — intervention group
Group type: COMPARATOR
Intervention: Placebo (raloxifene)
Number of subjects: 0
Study 39129524 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) palliative care intervention
Number of subjects: 0
Study 39129619 — intervention group
Group type: EXPERIMENTAL
Intervention: Lugol solution (7 days treatment)
Number of subjects: 56
Study 39129619 — intervention group
Group type: COMPARATOR
Intervention: No Lugol treatment (control group)
Number of subjects: 56
Study 39129649 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg daily
Number of subjects: 79
Study 39129649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 39129821 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention delivered by an intermediary to improve physical activity levels
Number of subjects: 30
Study 39129821 — intervention group
Group type: EXPERIMENTAL
Intervention: International Physical Activity Questionnaire - Short Form
Number of subjects: 30
Study 39129821 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Efficacy for Exercise Scale
Number of subjects: 30
Study 39129821 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Warwick Edinburgh Mental Well-being Scale
Number of subjects: 30
Study 39129821 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews
Number of subjects: 30
Study 39129921 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A levels in cord blood
Number of subjects: 140